Search research articles
Contact Us
Filters
Showing results (421-430 of 433) with videos related to
Page
of 44
Sort By:
Science (New York, N.Y.)
|
September 11, 2007
Educators have hard choices; nationally, not just in kansas
A White, W Meier, F Lovell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 8, 1997
Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes
J L Browning, I D Sizing, P Lawton, et al.
Annals of Surgical Oncology
|
February 20, 2009
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
P Harter, M Hahmann, H J Lueck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Zentralblatt Fur Gynakologie
|
February 2, 2006
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]
B Schmalfeldt, A du Bois, A Burges, et al.
British Journal of Cancer
|
January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study
F Trillsch, S Mahner, E Vettorazzi, et al.
Mabs
|
September 12, 2025
Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins
Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
F Trillsch, S Mahner, L Woelber, et al.
Page
of 44
Search research articles
Search
Showing results (421-430 of 433) with videos related to
Sort By:
Page
of 44
Science (New York, N.Y.)
|
September 11, 2007
Educators have hard choices; nationally, not just in kansas
A White, W Meier, F Lovell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2012
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K H Baumann, A du Bois, W Meier, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 8, 1997
Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes
J L Browning, I D Sizing, P Lawton, et al.
Annals of Surgical Oncology
|
February 20, 2009
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
P Harter, M Hahmann, H J Lueck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Zentralblatt Fur Gynakologie
|
February 2, 2006
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]
B Schmalfeldt, A du Bois, A Burges, et al.
British Journal of Cancer
|
January 7, 2015
Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study
F Trillsch, S Mahner, E Vettorazzi, et al.
Mabs
|
September 12, 2025
Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins
Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2014
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
F Trillsch, S Mahner, L Woelber, et al.
Page
of 44